Inactive Instrument

HBL - Hadasit Bio-Holdings Ltd TEL AVIV STOCK EXCHANGE

Equities

HDST

IL0010954050

Biotechnology & Medical Research

Cell Cure Neurosciences Ltd. announced that it expects to receive $5 million in funding from Hadasit Bio-Holdings, Ltd.

March 30, 2016

Cell Cure Neurosciences Ltd. announced that it will receive $5,000,000 in funding from existing investor, Hadasit Bio-Holdings, Ltd. on March 31, 2016. The company will issue convertible loan in the transaction.

Latest news about HBL - Hadasit Bio-Holdings Ltd

HBL - Hadasit Bio-Holdings Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
CEO of Pakistan's largest bank picked to lead country out of economic crisis	Mar. 11	RE
Pakistan's HBL CEO Aurangzeb resigns from bank, letter to bourse shows	Mar. 11	RE
Chief of Pakistan's largest bank likely to be included in new finance team, sources say	Mar. 05	RE
HBL - Hadasit Bio-Holdings Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-17	CI
Hadasit Bio-Holdings Ltd Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-19	CI
Hadasit Bio-Holdings, Ltd. Auditor Raises 'Going Concern' Doubt	17-03-29	CI
Cell Cure Neurosciences Ltd. announced that it expects to receive $1.6 million in funding from Hadasit Bio-Holdings, Ltd. and other investors.	16-11-20	CI
Cell Cure Neurosciences Ltd. announced that it expects to receive $3.5 million in funding from Hadasit Bio-Holdings, Ltd. and other investors	16-07-31	CI

Chart HBL - Hadasit Bio-Holdings Ltd

Duration

Period

More charts

Company Profile

HBL Hadasit Bio Holdings Ltd (Hadasit) is an investment company, a subsidiary of Hadassah Medical Organization (HMO). The Companyâs subsidiaries enable research and development and promote intellectual property (IP) to the medical and biotechnological industries. The Company together with its strategic partners, has established a number of start-up companies, and is assigned to commercialize that IP either through granting a product license to biotechnological or pharmaceutical companies or via the creation of a subsidiary which operates in the premise of HMO. Hadasit is equipped with resources and capabilities required for composing and conducting the pre-clinical services and clinical studies, establishing start-up companies, offering product licensing and providing international consulting services. The Companyâs framework serves to address investment in early-stage biotechnological star-ups, by distributing both risk and success amongst a number of companies.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.59B
MODERNA, INC.	+8.57%	40.65B
LONZA GROUP AG	+49.22%	40.57B
CELLTRION, INC.	-12.36%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.92%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.17B
MEDPACE HOLDINGS, INC.	+29.17%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.7B
UNITED THERAPEUTICS CORPORATION	+6.35%	11.1B

Other Biotechnology & Medical Research